Mechanisms of action of antiseizure drugs

Handbook of Clinical Neurology

Volumn 108, Issue , 2012, Pages 663-681

  Porter, Roger J ^a,b   Dhir, Ashish ^c   Macdonald, Robert L ^d   Rogawski, Michael A ^c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

ANIMAL; BIOLOGICAL MODEL; CLASSIFICATION; HISTORY; HUMAN; REVIEW; SEIZURE;

ANIMALS; ANTICONVULSANTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MODELS, BIOLOGICAL; SEIZURES;

EID: 84865579645     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52899-5.00021-6     Document Type: Chapter

References (202)

1. Amin J. A single hydrophobic residue confers barbiturate sensitivity to γ-aminobutyric acid type C receptor. Mol Pharmacol 1999, 55:411-423.
2. Ängehagen M., Ben-Menachem E., Rönnbäck L., et al. Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate. Neurochemical Res 2003, 28:333-340.
3. Arroyo S. Rufinamide. Neurotherapeutics 2007, 4:155-162.
4. Avery R.B., Johnston D. Multiple channel types contribute to the low-voltage-activated calcium current in hippocampal CA3 pyramidal neurons. J Neurosci 1996, 16:5567-5582.
5. Bajjalieh S.M., Frantz G.D., Weimann J.M., et al. Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci 1994, 14:5223-5235.
6. Barton M.E., Klein B.D., Wolf H.H., et al. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001, 47:217-227.
7. Bauer J., Cooper-Mahkorn D. Tiagabine: efficacy and safety in partial seizures - current status. Neuropsychiatr Dis Treat 2008, 4:731-736.
8. Baumel I.P., Gallagher B.B., DiMicco J., et al. Metabolism and anticonvulsant properties of primidone in the rat. J Pharmacol Exp Ther 1973, 186:305-314.
9. Ben-Menachem E., Persson L., Schechter P.J., et al. Effect of single doses of vigabatrin on CSF concentrations of GABA, homocamosine, homovanillic acid and 5-hydroxyindolacetic acid in patients with complex partial seizures. Epilepsy Res 1988, 2:96-101.
10. Ben-Menachem E., Persson L., Schechter P.J., et al. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol 1989, 271:799-859.
11. Borden L.A., Murali Dhar T.G., Smith K.E., et al. Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994, 269:219-224.
12. Bourgeois B.F.D., Dodson W.E., Ferrendelli J.A. Primdone, phenobarbital, and PEMA. I. Seizure protection, neurotoxicity, and therapeutic index of individual compounds in mice. Neurology 1983, 33:283.
13. Braga M.F., Aroniadou-Anderjaska V., Li H., et al. Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons. J Pharmacol Exp Ther 2009, 330:558-566.
14. Brandt C., Heile A., Potschka H., et al. Effects of the novel antiepileptic drug lacosamide on the development of amygdala kindling in rats. Epilepsia 2006, 47:1803-1809.
15. Brodie M.J. Tiagabine pharmacology in profile. Epilepsia 1995, 36:S7-S9.
16. Brodie M.J., Rosenfeld W.E., Vazquez B., et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009, 50:1899-1909.
17. Brown J.T., Randall A. Gabapentin fails to alter P/Q-type Ca2+ channel-mediated synaptic transmission in the hippocampus in vitro. Synapse 2005, 55:262-269.
18. Bryans J.S., Wustrow D.J. 3-Substituted GABA analogs with central nervous system activity: a review. Med Res Rev 1999, 19:149-177.
19. Buckley K., Kelly R.B. Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J Cell Biol 1985, 100:1284-1294.
20. Burdette D.E., Sackellares J.C. Felbamate pharmacology and use in epilepsy. Clin Neuropharmacol 1994, 17:389-402.
21. Campo-Soria C., Chang Y., Weiss D.S. Mechanism of action of benzodiazepines on GABAA receptors. Br J Pharmacol 2006, 148:984-990.
22. Chan-Palay V., Wu J.Y., Palay S.L. Immunocytochemical localization of γ-aminobutyric acid transaminase at cellular and ultrastructural levels. Proc Natl Acad Sci U S A 1979, 76:2067-2071.
23. Cheng-Hakimian A., Anderson G.D., Miller J.W. Rufinamide: pharmacology, clinical trials, and role in clinical practice. Int J Clin Pract 2006, 60:1497-1501.
24. Cheung H., Kamp D., Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992, 13:107-112.
25. Choi D., Stables J.P., Kohn H. Synthesis and anticonvulsant activities of N-benzyl-2-acetamidopropionamide derivatives. J Med Chem 1996, 39:1907-1916.
26. Coleman M.H., Yamaguchi S., Rogawski M.A. Protection against dendrotoxin-induced clonic seizures in mice by anticonvulsant drugs. Brain Res 1992, 575:138-142.
27. Coulter D.A. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in?. J Child Neurol 1997, 12:S2-S9.
28. Coulter D.A., Huguenard J.R., Prince D.A. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 1989, 25:582-593.
29. Coulter D.A., Huguenard J.R., Prince D.A. Specific petit mal anticonvulsants reduce calcium currents in thalamic neurons. Neurosci Lett 1989, 98:74-78.
30. Coulter D.A., Huguenard J.R., Prince D.A. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol 1989, 25:582-593.
31. Coulter D.A., Huguenard J.R., Prince D.A. Differential effects of petit mal anticonvulsants and convulsants on thalamic neurones: calcium current reduction. Br J Pharmacol 1990, 100:800-806.
32. Crunelli V., Leresche N. Block of thalamic T-type Ca2+ channels by ethosuximide is not the whole story. Epilepsy Curr 2002, 2:53-56.
33. Custer K.L., Austin N.S., Sullivan J.M., et al. Synaptic vesicle protein 2 enhances release probability at quiescent synapses. J Neurosci 2006, 26:1303-1313.
34. Czuczwar S.J., Borowicz K.K. Polytherapy in epilepsy: the experimental evidence. Epilepsy Res 2002, 52:15-23.
35. Dalby N.O. GABA-level increasing and anticonvulsant effects of three different GABA uptake inhibitors. Neuropharmacology 2000, 39:2399-2407.
36. Dodgson S.J., Shank R.P., Maryanoff B.E. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000, 41:S35-S39.
37. Dooley D.J., Taylor C.P., Donevan S., et al. Ca2+ channel α2δ ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007, 28:75-82.
38. Doty P., Rudd G.D., Stoehr T., et al. Lacosamide. Neurotherapeutics 2007, 4:145-148.
39. Elger C.E., Stefan H., Mann A., et al. A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res 2010, 88:255-263.
40. Errington A.C., Stöhr T., Heers C., et al. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels. Mol Pharmacol 2008, 73:157-169.
41. Feng H., Bianchi M.T., Macdonald R.L. Pentobarbital differentially modulates α1β3δ and α1β3γ2L GABAA receptor currents. Mol Pharmacol 2004, 66:988-1003.
42. Ffrench-Mullen J.M., Barker J.L., Rogawski M.A. Calcium current block by (-)-pentobarbital, phenobarbital, and CHEB but not (+)-pentobarbital in acutely isolated hippocampal CA1 neurons: comparison with effects on GABA-activated Cl- current. J Neurosci 1993, 13:3211-3221.
43. Fink-Jensen A., Suzdak P.D., Swedberg M.D., et al. The γ-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur J Pharmacol 1992, 220:197-201.
44. Frandsen A., Quistorff B., Schousboe A. Phenobarbital protects cerebral cortex neurones against toxicity induced by kainate but not by other excitatory amino acids. Neurosci Lett 1990, 111:233-238.
45. Gee N.S., Brown J.P., Dissanayake V.U.K., et al. The novel anticonvulsant drug, gabapentin (neurontin), binds to the α2δ subunit of a calcium channel. J Biol Chem 1996, 271:5768-5776.
46. Gibbs J.W., Sombati S., DeLorenzo R.J., et al. Cellular actions of topiramate: blockade of kainate-evoked inward currents in cultured hippocampal neurons. Epilepsia 2000, 41:S10-S16.
47. Godin Y., Heiner L., Mark J. Effects of di-n-propylacetate, an anticonvulsive compound, on GABA metabolism. J Neurochem 1969, 16:869-873.
48. Gomora J.C., Daud A.N., Weiergräber M., et al. Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol 2001, 60:1121-1132.
49. Gower A.J., Noyer M., Verloes R., et al. ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992, 222:193-203.
50. Gram L. Tiagabine: a novel drug with a GABAergic mechanism of action. Epilepsia 1994, 35:S85-S87.
51. Gram L., Larsson O.M., Johnsen A.H., et al. Effects of valproate, vigabatrin and aminooxyacetic acid on release of endogenous and exogenous GABA from cultured neurons. Epilepsy Res 1988, 2:87-95.
52. Gruber C.M., Brock J.T., Dyken M. Comparison of the effectiveness of phenobarbital mephobarbital, primidone, diphenylhydantion, ethotoin, metharbital and methyl phenylhydantoin in motor seizures. Clin Pharmacol Ther 1962, 3:23-28.
53. Grunze H., von Wegerer J., Greene R.W., et al. Modulation of calcium and potassium currents by lamotrigine. Neuropsychobiology 1998, 38:131-138.
54. Gryder D.S., Rogawski M.A. Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons. J Neurosci 2003, 23:7069-7074.
55. Gunthorpe M.J., Large C.H., Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia 2012, 53:412-424.
56. Hainsworth A.H., McNaughton N.C., Pereverzev A., et al. Actions of sipatrigine, 202 W92 and lamotrigine on R-type and T-type Ca2+ channel currents. Eur J Pharmacol 2003, 467:77-80.
57. Handley R., Stewart A.S. Mysoline; a new drug in the treatment of epilepsy. Lancet 1952, 1:742-744.
58. Harrison N.L., Simmonds M.A. Two distinct interactions of barbiturates and chlormethiazole with the GABAA receptor complex in rat cuneate nucleus in vitro. Br J Pharmacol 1983, 80:387-394.
59. Harty T.P., Rogawski M.A. Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res 2000, 39:47-55.
60. Hendrich J., Van Minh A.T., Heblich F., et al. Pharmacological disruption of calcium channel trafficking by the α2δ ligand gabapentin. Proc Natl Acad Sci U S A 2008, 105:3628-3633.
61. Huang C.W., Huang C.C., Wu S.N. Activation by zonisamide, a newer antiepileptic drug, of large-conductance calcium-activated potassium channel in differentiated hippocampal neuron-derived H19-7 cells. J Pharmacol Exp Ther 2007, 321:98-106.
62. Hughes J.R. Absence seizures: a review of recent reports with new concepts. Epilepsy Behav 2009, 15:404-412.
63. Ivanov S.V., Ward J.M., Tessarollo L., et al. Cerebellar ataxia, seizures, premature death, and cardiac abnormalities in mice with targeted disruption of the Cacna2d2 gene. Am J Pathol 2004, 165:1007-1018.
64. Jackson M.F., Esplin B., Čapek R. Reversal of the activity-dependent suppression of GABA-mediated inhibition in hippocampal slices from γ-vinyl GABA (vigabatrin)-pretreated rats. Neuropharmacology 2000, 39:65-74.
65. Jensen P.K. Felbamate in the treatment of Lennox-Gastaut syndrome. Epilepsia 2007, 35:S54-S57.
66. Johannessen C.U. Mechanisms of action of valproate: a commentatory. Neurochemistry International 2000, 37:103-110.
67. Jung M.F., Lippert B., Metcalf B.W., et al. Gamma-vinyl GABA (4-amino-hex-5- enoic acid), a new selective irreversible inhibitor of GABA-T: Effects on brain GABA metabolism in mice. J Neurochem 1977, 29:797-802.
68. Kalis M.M., Huff N.A. Oxcarbazepine, an antiepileptic agent. Clin Ther 2001, 23:680-700.
69. Kaminski R.M., Livingood M.R., Rogawski M.A. Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia 2004, 45:864-867.
70. Kaminski R.M., Banerjee M., Rogawski M.A. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004, 46:1097-1104.
71. Kaminski R.M., Gillard M., Leclercq K., et al. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia 2009, 50:1729-1740.
72. Kaminski R.M., Gillard M., Klitgaard H. Targeting SV2A for discovery of antiepileptic drugs. Jasper's Basic Mechanisms of the Epilepsies 2012, 974-983. Oxford University Press, New York. 4th edn. J.L. Noebels, M. Avoli, M.A. Rogawski (Eds.).
73. Kito M., Maehara M., Watanabe K. Antiepileptic drugs-calcium current interaction in cultured human neuroblastoma cells. Seizure 1994, 3:141-149.
74. Kito M., Maehara M., Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure 1996, 5:115-119.
75. Kleckner N.W., Glazewski J.C., Chen C.C., et al. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action. J Pharmacol Exp Ther 1999, 289:886-894.
76. Ko G.Y., Brown-Croyts L.M., Teyler T.J. The effects of anticonvulsant drugs on NMDA-EPSP, AMPA-EPSP, and GABA-IPSP in the rat hippocampus. Brain Res Bull 1997, 42:297-302.
77. Kobayashi T., Hirai H., Iino M., et al. Inhibitory effects of the antiepileptic drug ethosuximide on G protein-activated inwardly rectifying K+ channels. Neuropharmacology 2009, 56:499-506.
78. Koepp M.J., Edwards M., Collins J., et al. Status epilepticus and tiagabine therapy revisited. Epilepsia 2005, 46:1625-1632.
79. Kume A., Greenfield L.J., Macdonald R.L. Felbamate inhibits [3H]t-butylbicycloorthobenzoate (TBOB) binding and enhances Cl- current at the γ-aminobutyric acidA (GABAA) receptor. J Pharmacol Exp Ther 1996, 277:1784-1792.
80. Kuo C.C., Lin B.J., Chang H.R., et al. Use-dependent inhibition of the N-methyl-D-aspartate currents by felbamate: a gating modifier with selective binding to the desensitized channels. Mol Pharmacol 2004, 65:370-380.
81. Kuzniecky R., Ho S., Pan J., Martin R., et al. Modulation of cerebral GABA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 2002, 58:368-372.
82. Kyllerman M., Ben-Menachem E. Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res 1998, 29:109-114.
83. Lacinová L. Pharmacology of recombinant low-voltage activated calcium channels. Curr Drug Targets CNS Neurol Disord 2004, 3:105-111.
84. Lang D.G., Wang C.M. Lamotrigine and phenytoin interactions on ionic currents present in N4TG1 and GH3 clonal cells. Soc Neurosci Abstr 1991, 17:1256.
85. Lange W., Geißendörfer J., Schenzer A., et al. Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol 2009, 75:272-280.
86. Large C.H., Sokal D.M., Nehlig A., et al. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use. Epilepsia 2012, 53:425-436.
87. Leach M.J., Marden C.M., Miller A.A. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action. Epilepsia 1986, 27:490-497.
88. Leach M.J., Baxter M.G., Critchley M.A. Neurochemical and behavioral aspects of lamotrigine. Epilepsia 1991, 32:S4-S8.
89. Lees G., Leach M.A. Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Res 1993, 612:190-199.
90. Leresche N., Parri H.R., Erdemli G., et al. On the action of the anti-absence drug ethosuximide in the rat and cat thalamus. J Neurosci 1998, 18:4842-4853.
91. LeTiran A., Stables J.P., Kohn H. Functionalized amino acid anticonvulsants: synthesis and pharmacological evaluation of conformationally restricted analogues. Bioorg Med Chem 2001, 9:2693-2708.
92. Lennox W.G. The petit mal epilepsies: their treatment with tridione. J Am Med Assoc 1945, 129:1069-1074.
93. Lezzi M., Theander S., Janz R., et al. SV2A and SV2C are not vesicular Ca2+ transporters but control glucose-evoked granule recruitment. J Cell Sci 2005, 118:5647-5660.
94. Lin L.H., Wang L.H. Region-specific changes in GABAA receptor delta subunit mRNA level by tolerance to and withdrawal from pentobarbital. Neurosci Lett 1996, 202:149-152.
95. Loscher W. Valproate enhances GABA turnover in the substantia nigra. Brain Res 1989, 501:198-203.
96. Löscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 2002, 50:105-123.
97. Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002, 16:669-694.
98. Lynch B.A., Lambeng N., Nocka K., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 2004, 101:9861-9866.
99. Macdonald R.L. Anticonvulsant drug actions on neurons in cell culture. J Neural Transm 1988, 72:173-183.
100. Macdonald R.L. Antiepileptic drug actions. Epilepsia 1989, 30:S19-S28.
101. Macdonald R.L., Barker J.L. Different actions of anticonvulsant and anesthetic barbiturates revealed by use of cultured mammalian neurons. Science 1978, 200:775-777.
102. Macdonald R.L., Barker J.L. Benzodiazepines specifically modulate GABA-mediated postsynaptic inhibition in cultured mammalian neurons. Nature 1978, 271:563-564.
103. Macdonald R.L., Rogawski M.A. Cellular effects of antiepileptic drugs. Epilepsy: A Comprehensive Textbook 2008, 1433-1445. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia. 2nd edn. J. Engel, T.A. Pedley (Eds.).
104. Masuda Y., Ishizaki M., Shimizu M. Zonisamide: pharmacology and clinical efficacy in epilepsy. CNS Drug Rev 1998, 4:341-360.
105. Masuda Y., Karasawa T., Shiraishi Y., et al. 3-Sulfamoylmethyl-1,2-benzisoxazole, a new type of anticonvulsant drug: pharmacological profile. Arzneimittel-Forschung 1980, 30:477-483.
106. Matar N., Jin W., Wrubel H., et al. Zonisamide block of cloned human T-type voltage-gated calcium channels. Epilepsy Res 2009, 83:224-234.
107. McCabe R.T., Wasterlain C.G., Kucharczyk N., et al. Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J Pharmacol Exp Ther 1993, 264:1248-1252.
108. McLean M.J., Macdonald R.L. Multiple actions of phenytoin on mouse spinal cord neurons in cell culture. J Pharmacol Exp Ther 1983, 227:779-789.
109. McLean M.J., Macdonald R.L. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986, 237:1001-1011.
110. McLean M.J., Macdonald R.L. Carbamazepine and 10,11-epoxycarbamazepine produce use- and voltage-dependent limitation of rapidly firing action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986, 238:727-732.
111. McLean M.J., Bukhari A.A., Wamil A.W. Effects of topiramate on sodium-dependent action-potential firing by mouse spinal cord neurons in cell culture. Epilepsia 2007, 41:S21-S24.
112. Meldrum B.S., Chapman A.G. Basic mechanisms of Gabatril (tiagabine) and future potential developments. Epilepsia 1999, 40:S2-S6.
113. Mercado J., Czajkowski C. γ-Aminobutyric acid (GABA) and pentobarbital induce different conformational rearrangements in the GABAA receptor α1 and β2 pre-M1 regions. J Biol Chem 2008, 283:15250-15257.
114. Mikael A., Lars R., Elisabeth H., et al. Topiramate reduces AMPA-induced Ca2+ transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. J Neurochem 2005, 94:4.
115. Miller A.A., Wheatley P., Sawyer D.A., et al. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug. I. Anticonvulsant profile in mice and rats. Epilepsia 1986, 27:483-489.
116. Morimoto K., Sato H., Yamamoto Y., et al. Antiepileptic effects of tiagabine, a selective GABA uptake inhibitor, in the rat kindling model of temporal lobe epilepsy. Epilepsia 1997, 38:966-974.
117. Nielsen E.B., Suzdak P.D., Andersen K.E., et al. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991, 196:257-266.
118. Nishimori I., Vullo D., Innocenti A., et al. Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. Bioorg Med Chem Lett 2005, 15:3828-3833.
119. Noyer M., Gillard M., Matagne A., et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995, 286:137-146.
120. Okada M., Kaneko S., Hirano T., et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995, 22:193-205.
121. Okada M., Hirano T., Kawata Y., et al. Biphasic effects of zonisamide on serotonergic system in rat hippocampus. Epilepsy Res 1999, 34:187-197.
122. Olsen R.W., Li G.-D. GABAA receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation. Can J Anesth/J Can Anesth 2011, 58:206-215.
123. Olsen R.W., Sieghart W. International Union of Pharmacology. LXX. Subtypes of γ-aminobutyric acidA receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev 2008, 60:243-260.
124. Overstreet L.S., Westbrook G.L. Paradoxical reduction of synaptic inhibition by vigabatrin. J Neurophysiol 2001, 86:596-603.
125. Pearl P.L., Vezina L.G., Saneto R.P., et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009, 50:184-194.
126. Petersen E.N. DMCM: a potent convulsive benzodiazepine receptor ligand. Eur J Pharmacol 1983, 94:117-124.
127. Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurol Scand Suppl 1995, 162:31-34.
128. Petroff O.A., Behar K.L., Mattson R.H., et al. Human brain γ-aminobutyric acid level and seizure control following initiation of vigabatrin therapy. J Neurochem 1996, 67:2399-3404.
129. Petroff O.A.C., Hyder F., Mattson R.H., et al. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology 1999, 52:473.
130. Petroff O.A.C., Hyder F., Rothman D.L., et al. Topiramate rapidly raises brain GABA in epilepsy patients. Epilepsia 2001, 42:543-548.
131. Pisani A., Stefani A., Siniscalchi A., et al. Electrophysiological actions of felbamate on rat striatal neurones. Br J Pharmacol 1995, 116:2053-2061.
132. Poulsen C.F., Simeone T.A., Maar T.E. Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons. Neurochemical Res 2004, 29:275-282.
133. Prakriya M., Mennerick S. Selective depression of low-release probability excitatory synapses by sodium channel blockers. Neuron 2000, 26:671-682.
134. Reinikainen K.J., Keränen T., Halonen T., et al. Comparison of oxcarbazepine and carbamazepine: a double-blind study. Epilepsy Res 1987, 1:284-289.
135. Rho J.M., Donevan S.D., Rogawski M.A. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and γ-aminobutyric acidA receptors. Ann Neurol 1994, 35:229-234.
136. Rho J.M., Donevan S.D., Rogawski M.A. Direct activation of GABAA receptors by barbiturates in cultured rat hippocampal neurons. J Physiol 1996, 497:509-522.
137. Rho J.M., Donevan S.D., Rogawski M.A. Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther 1997, 280:1383-1391.
138. Riss J., Cloyd J., Gates J., et al. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008, 118:69-86.
139. Rock D.M., Macdonald R.L., Taylor C.P. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res 1989, 3:138-143.
140. Rogawski M.A. Principles of antiepileptic drug action. Antiepileptic Drugs 2002, 3-22. Lippincott Williams & Wilkins, Philadelphia. 5th edn. R.H. Levy, R.H. Mattson, B.S. Meldrum (Eds.).
141. Rogawski M.A. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res 2006, 69:273-294.
142. Rogawski M.A. Brivaracetam: a rational drug discovery success story. Br J Pharmacol. 2008, 154:1555-1557.
143. Rogawski M.A., Bazil C.W. New molecular targets for antiepileptic drugs: α2δ, SV2A, and Kv7/KCNQ/M potassium channels. Curr Neurol Neurosci Rep 2008, 8:345-352.
144. Rogawski M.A., Löscher W. The neurobiology of antiepileptic drugs. Nat Rev Neurosci 2004, 5:553-564.
145. Rogawski M.A., Porter R.J. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990, 42:223-286.
146. Rogers C.J., Twyman R.E., Macdonald R.L. Benzodiazepine and β-carboline regulation of single GABAA receptor channels of mouse spinal neurones in culture. J Physiol 1994, 475:69-82.
147. Sake J.K., Hebert D., Isojärvi J., et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010, 24:1055-1068.
148. Sarhan S., Seiler N. Metabolic inhibitors and subcellular distribution of GABA. J Neurosci Res 1979, 4:399-421.
149. Sayer R.J., Brown A.M., Schwindt P.C., et al. Calcium currents in acutely isolated human neocortical neurons. J Neurophysiol 1993, 69:1596-1606.
150. Schauf C.L. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987, 413:185-188.
151. Schmutz M., Brugger F., Gentsch C., et al. Oxcarbazepine: preclinical anticonvulsant profile and putative mechanisms of action. Epilepsia 2007, 35:S47-S50.
152. Schumacher T.B., Beck H., Steinhauser C., et al. Effects of phenytoin, carbamazepine, and gabapentin on calcium channels in hippocampal granule cells from patients with temporal lobe epilepsy. Epilepsia 1998, 39:355-363.
153. Segal M.M., Douglas A.F. Late sodium channel openings underlying epileptiform activity are preferentially diminished by the anticonvulsant phenytoin. J Neurophysiol 1997, 77:3021-3034.
154. Shah M.M., Migliore M., Brown D.A. Differential effects of Kv7 (M-) channels on synaptic integration in distinct subcellular compartments of rat hippocampal pyramidal neurons. J Physiol 2011, 589(Pt 24):6029-6038.
155. Sheets P.L., Heers C., Stoehr T., et al. Differential block of sensory neuronal voltage-gated sodium channels by lacosamide [(2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide], lidocaine, and carbamazepine. J Pharmacol Exp Ther 2008, 326:89-99.
156. Sierra-Paredes G., Sierra-Marcuño G. Extrasynaptic GABA and glutamate receptors in epilepsy. CNS Neurol Disord Drug Targets 2007, 6:288-300.
157. Simeone T.A., Otto J.F., Wilcox K.S., et al. Felbamate is a subunit selective modulator of recombinant γ-aminobutyric acid typeA receptors expressed in Xenopus oocytes. Eur J Pharmacol 2006, 552:31-35.
158. Simeone T.A., Wilcox K.S., White H.S. Subunit selectivity of topiramate modulation of heteromeric GABAA receptors. Neuropharmacology 2006, 50:845-857.
159. Smith S.E., Parvez N.S., Chapman A.G., et al. The γ-aminobutyric acid uptake inhibitor, tiagabine, is anticonvulsant in two animal models of reflex epilepsy. Eur J Pharmacol. 1995, 273:259-265.
160. Snell G.D. Ducky, a new second chromosome mutation in the mouse. J Hered 1955, 46:27-29.
161. Stefani A., Calabresi P., Pisani A., et al. Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. J Pharmacol Exp Ther 1996, 277:121-127.
162. Stefani A., Spadoni F., Bernardi G. Gabapentin inhibits calcium currents in isolated rat brain neurons. Neuropharmacology 1998, 37:83-91.
163. Stefani A., Pisani A., Murtas M.D., et al. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of high-voltage-activated calcium currents. Epilepsia 2005, 36:997-1002.
164. Stohr T., Stables J.P., Wilcox K., et al. The pre-clinical profile of the novel anticonvulsant lacosamide. Epilepsia 2005, 46:373.
165. Suzdak P.D., Jansen J.A. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995, 36:612-626.
166. Suzuki S., Rogawski M.A. T-type calcium channels mediate the transition between tonic and phasic firing in thalamic neurons. Proc Natl Acad Sci U S A 1989, 86:7228-7232.
167. Suzuki S., Kawakami K., Nishimura S., et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992, 12:21-27.
168. Tatulian L., Brown D.A. Effect of the KCNQ potassium channel opener retigabine on single KCNQ2/3 channels expressed in CHO cells. J Physiol 2003, 549(Pt 1):57-63.
169. Taverna S., Mantegazza M., Franceschetti S., et al. Valproate selectively reduces the persistent fraction of Na+ current in neocortical neurons. Epilepsy Res 1998, 32:304-308.
170. Taylor L.A., McQuade R.D., Tice M.A. Felbamate, a novel antiepileptic drug, reverses N-methyl-D-aspartate/glycine-stimulated increases in intracellular Ca2+ concentration. Eur J Pharmacol 1995, 289:229-233.
171. Thöne J., Leniger T., Splettstösser F., et al. Antiepileptic activity of zonisamide on hippocampal CA3 neurons does not depend on carbonic anhydrase inhibition. Epilepsy Res 2008, 79:105-111.
172. Todorovic S.M., Lingle C.J. Pharmacological properties of T-type Ca2+ current in adult rat sensory neurons: effects of anticonvulsant and anesthetic agents. J Neurophysiol 1998, 79:240-252.
173. Toman J.E.P. The neuropharmacology of antiepileptics. Electroencephalogr Clin Neurophysiol 1949, 1:33-44.
174. Tran-Van-Minh A., Dolphin A.C. The α2δ ligand gabapentin inhibits the Rab11-dependent recycling of the calcium channel subunit α2δ-2. J Neurosci 2010, 30:12856-12867.
175. Tuttle J.B., Richelson E. Phenytoin action on the excitable membrane of mouse neuroblastoma. J Pharmacol Exp Ther 1979, 211:632-637.
176. Van Dongen A.M.J., Van Erp M.G., Voskuyl R.A. Valproate reduces excitability by blockage of sodium and potassium conductance. Epilepsia 1986, 27:177-182.
177. van Hooft J.A., Dougherty J.J., Endeman D., et al. Gabapentin inhibits presynaptic Ca2+ influx and synaptic transmission in rat hippocampus and neocortex. Eur J Pharmacol 2002, 449:221-228.
178. Vazda F.J.E. New antiepileptic drugs. J Clin Neurosci 2000, 7:88-101.
179. Vega D., Maalouf N.M., Sakhaee K. Increased propensity for calcium phosphate kidney stones with topiramate use. Expert Opin Drug Saf 2007, 6:547-557.
180. Victor B. Clinical pharmacology and mechanism of action of zonisamide. Clin Neuropharmacol 2007, 30:230-240.
181. Vinogradova L.V., Kuznetsova G.D., Shatskova A.B., et al. Vigabatrin in low doses selectively suppresses the clonic component of audiogenically kindled seizures in rats. Epilepsia 2005, 46:800-810.
182. Wamil A.W., McLean M.J. Phenytoin blocks N-methyl-D-aspartate responses of mouse central neurons. J Pharmacol Exp Ther 1993, 267:218-227.
183. Wamil A.W., Schmutz M., Portet C., et al. Effects of oxcarbazepine and 10-hydroxycarbamazepine on action potential firing and generalized seizures. Eur J Pharmacol 1994, 271:301-308.
184. Wamil A.W., Löscher W., McLean M.J. Trans-2-en-valproic acid limits action potential firing frequency in mouse central neurons in cell culture. J Pharmacol Exp Ther 1997, 280:1349-1356.
185. Wang Z., Silverman R.B. Synthesis of cyclopropane isosteres of the antiepilepsy drug vigabatrin and evaluation of their inhibition of GABA aminotransferase. J Enzyme Inhib Med Chem 2004, 19:293-301.
186. Wang S.J., Huang C.C., Hsu K.S., et al. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport 1996, 7:3037-3040.
187. Wang M., Offord J., Oxender D.L., et al. Structural requirement of the calcium-channel subunit α2δ for gabapentin binding. Biochem J 1999, 342:313-320.
188. Wang S.J., Sihra T.S., Gean P.W. Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity. Neuroreport 2001, 12:2255-2258.
189. Wang Y., Park K.D., Salome C., et al. Development and characterization of novel derivatives of the antiepileptic drug lacosamide that exhibit far greater enhancement in slow inactivation of voltage-gated sodium channels. ACS Chem Neurosci 2011, 2:90-106.
190. White H.S. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 2005, 45:S48-S56.
191. White H.S., Harmsworth W.L., Sofia R.D., et al. Felbamate modulates the strychnine-insensitive glycine receptor. Epilepsy Res 1995, 20:41-48.
192. White H.S., Brown S.D., Woodhead J.H., et al. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997, 28:167-179.
193. White H.S., Wolf H.H., Swinyard E.A., et al. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia 2005, 33:564-572.
194. Willow M., Gonoi T., Catterall W.A. Voltage clamp analysis of the inhibitory actions of diphenylhydantoin and carbamazepine on voltage-sensitive sodium channels in neuroblastoma cells. Mol Pharmacol 1985, 27:549-558.
195. Wuttke T.V., Seebohm G., Bail S., et al. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol Pharmacol 2005, 67:1009-1017.
196. Xiong Z.G., Chu X.P., MacDonald J.F. Effect of lamotrigine on the Ca2+-sensing cation current in cultured hippocampal neurons. J Neurophysiol 2001, 86:2520-2526.
197. Xu T., Bajjalieh S.M. SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol 2001, 3:691-698.
198. Yamaguchi S., Rogawski M.A. Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res 1992, 11:9-16.
199. Yang J., Wetterstrand C., Jones R.S. Felbamate but not phenytoin or gabapentin reduces glutamate release by blocking presynaptic NMDA receptors in the entorhinal cortex. Epilepsy Res 2007, 77:157-164.
200. Zhang X., Velumian A.A., Jones O.T., et al. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia 2005, 41:52-60.
201. Zona C., Tancredi V., Palma E., et al. Potassium currents in rat cortical neurons in culture are enhanced by the antiepileptic drug carbamazepine. Can J Physiol Pharmacol 1990, 68:545-547.
202. Zona C., Ciotti M.T., Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 1997, 231:123-126.